Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dysport for Spasticity in MS (LINITOX)
NCT04595045Phase 3Completed
- Start
- Jan 2019
- Primary completion
- Jul 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of botulinum toxin type A in spasticity. Started Jan 2019; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
spasticity
Beyond the preview
Go deeper on NCT04595045.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04595045.